BCLI·10501E201·US·equity·Healthcare - Biotechnology-13D/G
BCLI (BrainStorm Cell Therapeutics In) is held by 0 institutional investors as of Q4 2025. Net institutional sentiment: Bearish.
No institutional consensus yet
Fewer than 2 tracked funds currently hold BCLI (BrainStorm Cell Therapeutics In). We surface convergence signals once 2+ institutional funds, insiders, or activists take a position.
This is the correct empty state for thinly-held stocks, not a data issue. New 13F filings arrive quarterly; insider and activist filings update daily.
Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer